TIGCRU were asked to provide commercial input to the evaluation of a licensing opportunity for a top 10 pharma company. The evaluation was to include a review of the proposed launch strategy for the product and development of a patient based forecast model.
Providing an understanding of the current treatment algorithm in the disease area, and assessing the impact of the new product on clinical practice was critical in defining drivers and barriers to change.
However, there was very little published data in this particular disease area, so we sought to increase robustness in our forecast with a piece of rapid turnaround internet research with our key customer group. Within 5 working days we were able to gain input from >90 customers, analyse results and update our forecast model.
We presented our full evaluation and report to the client leadership team, thus informing a major decision point.